Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments Novo Holdings has invested in a $200M Series A financing for Windward Bio, aiming to develop innovative treatments for asthma and COPD with a focus on long-acting therapies.

Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments #Novo_Holdings #Denmark #Copenhagen #Windward_Bio #WIN378